Omada Health delivered a significant beat for the third quarter 2026, reporting revenue of $91.3 million and its third consecutive quarter of GAAP profitability. The results reflect strong momentum in its cardiometabolic platform and significant margin expansion as the company achieves greater operating leverage.
Key Highlights
- Quarterly revenue grew 34% year-over-year to $91.3 million, surpassing the consensus estimate of $85.65 million.
- GAAP gross margin expanded to 76%, a 1,000 basis point improvement from the 66% reported in the third quarter 2025.
- Total members reached a record 1.1 million, a 36% increase year-over-year, driven by diabetes and hypertension program enrollment.
- Management raised full-year 2026 revenue guidance to a range of $344 million to $346 million, up from the prior range of $334 million to $340 million.